Hematology (all articles)
Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy.
8 Jul, 2022 | 11:53h | UTCRelated:
AHA Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis.
RCT | Efficacy and safety of a Pegasparaginase-based chemotherapy regimen vs. an L-asparaginase–based chemotherapy regimen for newly diagnosed advanced extranodal Natural Killer/T-Cell Lymphoma.
8 Jul, 2022 | 11:21h | UTCEfficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Editorial: De-escalating Chemotherapy for Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Step Toward Improved Treatment of a Rare Virus-Associated Cancer – JAMA Oncology (free for a limited period)
See also: Visual Abstract
Review | Sickle cell disease.
7 Jul, 2022 | 12:59h | UTCSickle Cell Disease: A Review – JAMA (free for a limited period)
Audio Clinical Review: Sickle Cell Disease – JAMA
Coagulation and transfusion updates from 2021.
7 Jul, 2022 | 12:36h | UTCCoagulation and Transfusion Updates from 2021 – Journal of Cardiothoracic and Vascular Anesthesia
M-A | DOACs vs. VKAs in atrial fibrillation patients with bioprosthetic heart valve.
7 Jul, 2022 | 12:15h | UTC
M-A | Anticoagulants for thrombosis prophylaxis in acutely ill patients admitted to hospital.
5 Jul, 2022 | 12:19h | UTCCohort Study | Treatment outcomes and roles of transplantation and maintenance rituximab in patients with previously untreated mantle cell lymphoma.
5 Jul, 2022 | 11:39h | UTCNews Release: Mantle cell lymphoma treatment varies according to setting – Weill Cornell Medicine
EM Cases | The 7 Ts of massive hemorrhage protocols.
5 Jul, 2022 | 11:35h | UTCEM Cases: The 7 Ts of Massive Hemorrhage Protocols – emDocs
RCT | CT vs. [18F]FDG-PET-CT for persistent or recurrent neutropenic fever in high-risk patients.
4 Jul, 2022 | 12:21h | UTC[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: [18F]FDG-PET-CT resulted in more frequent antimicrobial rationalisation than CT in patients w/ haem diseases & persistent/recurrent high-risk neutropenic fever after chemotherapy. Results of the ph3 RCT PIPPIN #radonc #hemonc https://t.co/isOPFZVVpY pic.twitter.com/PVd8yFy7Ck
— The Lancet Haematology (@TheLancetHaem) June 29, 2022
FDA warns about possible increased risk of death and serious side effects with duvelisib.
4 Jul, 2022 | 11:51h | UTC2022 Guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
1 Jul, 2022 | 11:50h | UTCRelated:
Editorial | Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time?
4 Jul, 2022 | 11:48h | UTCOriginal Studies:
Two new studies show no benefit of Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19.
1 Jul, 2022 | 11:49h | UTCCommentaries:
Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (free registration required)
Commentary on Twitter (thread – click for more)
Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓
Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA
Now, we publish the OVID and ETHIC trials?
— The Lancet Haematology (@TheLancetHaem) June 30, 2022
RCT: Prothrombin complex concentrate vs. plasma for post–cardiopulmonary bypass coagulopathy and bleeding.
30 Jun, 2022 | 10:50h | UTCProthrombin Complex Concentrate vs Plasma for Post–Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)
Commentary on Twitter
In this RCT of cardiac surgical patients, there was no significant difference in postoperative bleeding among patients receiving prothrombin complex concentrates (PCCs) or plasma. Fewer patients with PCCs required intraoperative RBCs after treatment. https://t.co/vqtNX7hQxA
— JAMA Surgery (@JAMASurgery) June 29, 2022
Single-arm phase II study: Venetoclax added to Cladribine plus low-dose Cytarabine alternating with 5-Azacitidine in older patients with newly diagnosed acute myeloid leukemia.
30 Jun, 2022 | 10:14h | UTCPhase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia – Journal of Clinical Oncology (link to abstract – $ for full-text)
Cohort Study: Burden of long-term morbidity borne by survivors of acute myeloid leukemia treated with blood or marrow transplantation.
29 Jun, 2022 | 10:56h | UTC
Commentary on Twitter
We must understand life after BMT better, what it MEANS for a patient surviving intensive but curative treatment. Kudos to this @JCO_ASCO paper but we need better designs: versus other treatments, in BMT cohorts!
Life's gray, not categorical…#bmtsmhttps://t.co/E4YQV4LzoN pic.twitter.com/P7bMWXMTB5— Nico Gagelmann (@NicoGagelmann) June 23, 2022
Under a https://creativecommons.org/licenses/by-nc-nd/4.0/ license
Brief Review | Never above suspicion: getting to the bottom of cardiac sarcoidosis diagnosis and treatment.
29 Jun, 2022 | 10:50h | UTC
The 5th edition of the WHO classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms.
27 Jun, 2022 | 11:40h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
The 5th edition of the WHO classification of hematolymphoid tumors: lymphoid neoplasms.
27 Jun, 2022 | 11:38h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.
24 Jun, 2022 | 11:13h | UTC
M-A: Intravenous iron vs. oral iron vs. no iron with or without erythropoiesis‐ stimulating agents for cancer patients with anemia.
23 Jun, 2022 | 10:10h | UTC
5-year follow up of a RCT: Ruxolitinib versus best available therapy in inadequately controlled polycythemia vera without splenomegaly.
23 Jun, 2022 | 09:55h | UTCRuxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
NEW online—5-year follow up of RESPONSE-2, a randomised, phase 3b study, supports the use of ruxolitinib as a second-line therapy of choice for patients with inadequately controlled polycythaemia vera without splenomegaly #mpnsm https://t.co/yuENmcJv0P pic.twitter.com/aogZJ6gonW
— The Lancet Haematology (@TheLancetHaem) May 19, 2022
RCT: Lisocabtagene maraleucel vs. standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma.
21 Jun, 2022 | 10:48h | UTCLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Single-arm Phase II trial: Direct-acting antivirals as primary treatment for hepatitis C virus–associated indolent Non-Hodgkin Lymphomas.
20 Jun, 2022 | 00:51h | UTC
10-year outcomes of a RCT: Time to cure for childhood and young adult Acute Lymphoblastic Leukemia is independent of early risk factors.
20 Jun, 2022 | 00:49h | UTCTime to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)